Maturation of blood vessels by haematopoietic stem cells and progenitor cells: Involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation

Summary

Apelin is a recently-isolated bioactive peptide from bovine gastric extract. The gene encodes a protein of 77 amino acids, which can generate two active polypeptides, long (42–77) and short (65–77). Both peptides ligate and activate APJ, a G protein-coupled receptor expressed in the cardiovascular and central nervous systems. Although an essential role for the apelin/APJ system in blood vessel formation has been reported in Xenopus, its precise function in mammals is unclear. Blood vessel tube formation is accomplished by two main mechanisms: 1) single cell hollowing, in which a lumen forms within the cytoplasm of a single endothelial cell (EC), and 2) cord hollowing in which a luminal cavity is created de novo between ECs in a thin cylindrical cord. Molecular control of either single cell or cord hollowing has not been precisely determined. Angiopoietin-1 (Ang1) has been reported to induce enlargement of blood vessels. Apelin is produced from ECs upon activation of Tie2, a cognate receptor of Ang1, expressed on ECs. It has been suggested that apelin induces cord hollowing by promoting proliferation and aggregation/assembly of ECs. During angiogenesis, haematopoietic stem cells (HSCs) and progenitor cells (HPCs) are frequently observed in the perivascular region. They produce Ang1 and induce migration of ECs, resulting in a fine vascular network. Moreover, HSCs/HPCs can induce apelin production from ECs. Therefore, this review article posits that HSCs/HPCs regulate caliber size of blood vessels via apelin/APJ and Angiopoietin/Tie2 interactions.

Keywords

Haematopoietic stem cell - haematopoietic progenitor cells - Tie2 - Angiopoietin-1 - Apelin, APJ

• References

• 1 Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
• 2 Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13: 1055-1066.
• 3 Oettgen P. Transcriptional regulation of vascular development. Circ Res 2001; 89: 380-383.
• 4 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
• 5 Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15-23.
• 6 Simon MC. Vascular morphogenesis and the formation of vascular networks. Dev Cell 2004; 6: 479-482.
• 7 Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93: 741-753.
• 8 Adams RH, Wilkinson GA, Weiss C. et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306.
• 9 Zhong TP, Childs S, Leu JP. et al. Gridlock signalling pathway fashions the first embryonic artery. Nature 2001; 414: 216-220.
• 10 Morawietz H, Breier G. Endothelial cell biology: an update. 5th International Symposium on the Biology of Endothelial Cells. Thromb Haemost 2006; 95: 1025-1030.
• 11 Lindahl P, Johansson BR, Leveen P. et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
• 12 Dumont DJ, Gradwohl G, Fong GH. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897-1909.
• 13 Sato TN, Tozawa Y, Deutsch U. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70-74.
• 14 Suri C, Jones PF, Patan S. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180.
• 15 Feng Y, vom Hagen F, Pfister F. et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007; 97: 99-108.
• 16 Lubarsky B, Krasnow MA. Tube morphogenesis: making and shaping biological tubes. Cell 2003; 112: 19-28.
• 17 Kamei M, Saunders WB, Bayless KJ. et al. Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 2006; 442: 453-456.
• 18 Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980; 288: 551-556.
• 19 Parker LH, Schmidt M, Jin SW. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004; 428: 754-758.
• 20 Suri C, McClain J, Thurston G. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
• 21 Cho CH, Kim KE, Byun J. et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res 2005; 97: 86-94.
• 22 Thurston G, Wang Q, Baffert F. et al. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 2005; 132: 3317-3326.
• 23 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
• 24 Kidoya H, Ueno M, Yamada Y. et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008; 27: 522-534.
• 25 Tatemoto K, Hosoya M, Habata Y. et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-476.
• 26 Kawamata Y, Habata Y, Fukusumi S. et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538: 162-171.
• 27 Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005; 17: 415-426.
• 28 O’Dowd BF, Heiber M, Chan A. et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-360.
• 29 Devic E, Rizzoti K, Bodin S. et al. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 1999; 84: 199-203.
• 30 Edinger AL, Hoffman TL, Sharron M. et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998; 72: 7934-7940.
• 31 Croitoru-Lamoury J, Guillemin GJ, Boussin FD. et al. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia 2003; 41: 354-370.
• 32 De Mota N, Reaux-Le Goazigo A, El Messari S. et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA 2004; 101: 10464-10469.
• 33 Devic E, Paquereau L, Vernier P. et al. Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev 1996; 59: 129-140.
• 34 Katugampola SD, Maguire JJ, Matthewson SR. et al. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001; 132: 1255-1260.
• 35 Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004; 118: 119-125.
• 36 Szokodi I, Tavi P, Foldes G. et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91: 434-440.
• 37 Ashley EA, Powers J, Chen M. et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65: 73-82.
• 38 Ishida J, Hashimoto T, Hashimoto Y. et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 26274-26279.
• 39 Tatemoto K, Takayama K, Zou MX. et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99: 87-92.
• 40 Inui M, Fukui A, Ito Y. et al. Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev Biol 2006; 298: 188-200.
• 41 Cox CM, D’Agostino SL, Miller MK. et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296: 177-189.
• 42 Scott IC, Masri B, D’Amico LA. et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell 2007; 12: 403-413.
• 43 Kalin RE, Kretz MP, Meyer AM. et al. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007; 305: 599-614.
• 44 Takahashi T, Yamaguchi S, Chida K. et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20: 2768-2778.
• 45 Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 2007; 97: 355-363.
• 46 Masri B, Morin N, Cornu M. et al. Apelin (65–77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004; 18: 1909-1911.
• 47 Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998; 143: 1341-1352.
• 48 Grant DS, Lelkes PI, Fukuda K. et al. Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro. In Vitro Cell Dev Biol 1991; 27: 327-336.
• 49 Nicosia RF, Madri JA. The microvascular extracellular matrix. Developmental changes during angiogenesis in the aortic ring-plasma clot model. Am J Pathol 1987; 128: 78-90.
• 50 Davis S, Aldrich TH, Jones PF. et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169.
• 51 Takakura N, Watanabe T, Suenobu S. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000; 102: 199-209.
• 52 Okamoto R, Ueno M, Yamada Y. et al. Hematopoietic cells regulate the angiogenic switch during tumorigenesis. Blood 2005; 105: 2757-2763.
• 53 Yamada Y, Takakura N. Physiological pathway of differentiation of hematopoietic stem cell population into mural cells. J Exp Med 2006; 203: 1055-1065.
• 54 Okuda T, van Deursen J, Hiebert SW. et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
• 55 Okada H, Watanabe T, Niki M. et al. AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Oncogene 1998; 17: 2287-2293.
• 56 Sata M, Saiura A, Kunisato A. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
• 57 Huang PP, Yang XF, Li SZ. et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98: 1335-1342.